Crossmark

AFM13: a first-in-class tetravalent bispecific anti-CD30/CD16A antibody for NK cell-mediated immunotherapy

Crossref DOI link: https://doi.org/10.1186/s13045-015-0188-3

Published Online: 2015-08-01

Published Print: 2015-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Wu, Jingjing

Fu, Jiaping

Zhang, Mingzhi

Liu, Delong
License Information

License valid from 2015-08-01
More Information

Article History

Received: 4 July 2015

Accepted: 16 July 2015

First Online: 1 August 2015